Gen9 and SynbiCITE Announce Partnership to Accelerate Technology Commercialization through Synthetic Biology
- Posted on 17 February, 2016
Gen9 synthetic DNA to fuel innovations by SynbiCITE community
Cambridge, MA and UK, 17th February 2016 / Gen9, a leader in the development of scalable technologies for synthesizing and assembling DNA, and SynbiCITE, a pioneering Innovation and Knowledge Centre (IKC) dedicated to promoting adoption and usage of synthetic biology, today announced a partnership that provides members of the SynbiCITE research community access to Gen9’s high-throughput BioFab® platform for gene synthesis.
“Synthetic biology has been named one of the eight great British technologies of the future. It has enormous potential to advance the research of our members who are working on many societal challenges, from pollution to hunger to disease,” said John Collins, Ph.D., Commercial Director at SynbiCITE. “Gen9’s DNA synthesis technologies will be an invaluable resource to our members. These types of industry partnerships enable faster commercialization of breakthrough technologies in the space.”
Since 2013, SynbiCITE has been fostering innovation and collaboration with a goal of accelerating the commercialization of synthetic biology products, tools and processes. Members receive access to education, funding opportunities, laboratory facilities and the latest synthetic biology technologies. SynbiCITE is funded by the UK Research Councils, Engineering and Physical Sciences Research Council (EPSRC), Biotechnology and Biological Sciences Research Council (BBSRC), Innovate UK, and its industrial and academic partners.
Central to the Gen9 and SynbiCITE collaboration is Gen9’s BioFab® platform for manufacture of high-quality, low-cost synthetic DNA at unprecedented scale and accuracy. With access to this technology, scientists can design more powerful experiments and test many hypotheses simultaneously, resulting in faster and more effective research outcomes.
“Our mission is to empower scientists through the limitless possibilities of synthetic biology,” said Kevin Munnelly, President and CEO of Gen9. “We are excited to collaborate with SynbiCITE, a visionary organization that shares our goal of making synthetic biology accessible to all researchers. We look forward to the cutting-edge advancements that will be realized through our partnership.”
Gen9 is the premier next-generation gene synthesis company focused on high-quality, high-throughput, automated production of DNA constructs. The Gen9 technology allows for the lowest-cost and highest-quality DNA constructs commercially available. Founded by world leaders in synthetic biology, Gen9 aims to ensure the constructive application of synthetic biology in industries ranging from enzyme and chemical production to pharmaceuticals and biofuels. Gen9 is powering the synthetic biology revolution from our headquarters in Cambridge, Massachusetts. Visit Gen9 at www.gen9bio.com.
SynbiCITE is a pioneering Innovation and Knowledge Centre (IKC) dedicated to promoting the adoption and use of synthetic biology by industry. SynbiCITE and our partners across the UK and globally are committed to developing this technology through responsible innovation which encompasses ethical, societal and environmental considerations.
SynbiCITE is focused at Imperial College London and is, with our partners, accelerating the commercialisation of world-class science and the emerging technologies encompassed by synthetic biology into new products, tools, processes and services. Our overall aim is to grow UK industry in the sector and improve synthetic biology, using industry to achieve significant economic impact, generate wealth for the companies, generate skilled workers and create jobs. Visit SynbiCITE at www.synbicite.com.
Chempetitive Group for Gen9
Tel: +1 617-823-5555
Sciad Communications for SynbiCITE
Tel: +44 7973 950376
Share this article:
People also read
Evonetix establishes scientific advisory board
CAMBRIDGE, UK, 20 December 2018 – EVONETIX LTD (‘Evonetix’), the Cambridge-based company pioneering an innovative approach to scalable and high-fideli...
Synthetic biology start-up Colorifix raises $3m Series A round to scale its revolutionary textile dyeing solution
Colorifix, a company that has developed the first commercial biological dyeing process, has raised a Series A round of $3 million from impact and stra...
Evonetix wins Best Emerging Synthetic Biology Company at the OBN Awards
London, UK, 12th October 2018 / Sciad Newswire / SynbiCITE would like to congratulate Evonetix on winning ‘Best Emerging Synthetic Biology Company’ at...